← All Provectus Biopharmaceuticals, INC filings

Provectus Biopharmaceuticals, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

OQB
PVCT
Provectus Biopharmaceuticals, INC
10-K/A: Provectus Biopharmaceuticals Files Amendment No. 1 to 2024 Annual Report on Form 10-K/A
Provectus Biopharmaceuticals files an amendment to its 2024 annual report to include previously omitted information regarding directors, executive officers, and corporate governance.
OQB
PVCT
Provectus Biopharmaceuticals, INC
10-K: Provectus Biopharmaceuticals Reports Annual Results, Highlights Ongoing Development and Financial Strategy
Provectus Biopharmaceuticals details its clinical development programs, intellectual property advancements, and financial strategies in its annual report for the year ended December 31, 2024, while acknowledging substantial doubt about its ability to continue as a going concern.
OQB
PVCT
Provectus Biopharmaceuticals, INC
10-K/A: Provectus Biopharmaceuticals Files Amended 10-K Report Following Proxy Statement Delay
Provectus Biopharmaceuticals has filed an amendment to its annual report to include required information omitted due to a delay in filing its definitive proxy statement.
OQB
PVCT
Provectus Biopharmaceuticals, INC
10-K: Provectus Biopharmaceuticals Reports on Financials and Operations in Annual 10-K Filing
Provectus Biopharmaceuticals details its financial status, ongoing research, and intellectual property in its annual 10-K filing, highlighting its clinical-stage development of immunotherapy medicines.